Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective, Real-world study to evaluate the clinical outcomes with radium-223 in metastatic castration-resistant prostate cancer patients previously treated with abiraterone or enzalutamide

Next Previous
Trial Profile

A Retrospective, Real-world study to evaluate the clinical outcomes with radium-223 in metastatic castration-resistant prostate cancer patients previously treated with abiraterone or enzalutamide

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone (Primary) ; Enzalutamide (Primary) ; Prednisone (Primary) ; Radium 223 chloride (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bayer

Most Recent Events

  • 04 Jun 2019 Results assessing real-world symptomatic skeletal events (SSEs) and overall survival (OS) of patients with mCRPC who received concurrent or layered Ra-223 plus Enza or abiraterone plus prednisone/prednisolone, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
  • 13 May 2019 According to a Bayer media release, data from this study will be presented in the upcoming 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019, taking place May 31 to June 4 in Chicago, Illinois (USA).
  • 16 Feb 2019 Results of radium-223 and abiraterone cohort presented at the 2019 Genitourinary Cancers Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top